作者
Andreea A Artenie, Evan B Cunningham, Gregory J Dore, Brian Conway, Olav Dalgard, Jeff Powis, Philip Bruggmann, Margaret Hellard, Curtis Cooper, Philip Read, Jordan J Feld, Behzad Hajarizadeh, Janaki Amin, Karine Lacombe, Catherine Stedman, Alain H Litwin, Pip Marks, Gail V Matthews, Sophie Quiene, Amanda Erratt, Julie Bruneau, Jason Grebely
发表日期
2020/5/23
期刊
Clinical Infectious Diseases
卷号
70
期号
11
页码范围
2369-2376
出版商
Oxford University Press
简介
Background
In many settings, recent or prior injection drug use remains a barrier to accessing direct-acting antiviral treatment (DAA) for hepatitis C virus (HCV) infection. We examined patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment (OAT) during and following DAA-based treatment.
Methods
SIMPLIFY and D3FEAT are phase 4 trials evaluating the efficacy of DAA among people with past 6-month injecting drug use or receiving OAT through a network of 25 international sites. Enrolled in 2016–2017, participants received sofosbuvir/velpatasvir (SIMPLIFY) or paritaprevir/ritonavir/dasabuvir/ombitasvir ± ribavirin (D3FEAT) for 12 weeks and completed behavioral questionnaires before, during, and up to 2 years posttreatment. The impact of time in HCV treatment and follow-up on …
学术搜索中的文章
AA Artenie, EB Cunningham, GJ Dore, B Conway… - Clinical Infectious Diseases, 2020